Publication number: 20260199533
Abstract: It is an object of the present invention to provide drugs that bind specifically to FAP?, are effective in the treatment and diagnosis of tumors or cancers expressing FAP?, for example, in the treatment and diagnosis of solid cancers such as pancreatic cancer, sarcoma, esophageal cancer, lung cancer, breast cancer, prostate cancer, head and neck cancer, ovarian cancer, colon cancer, neuroendocrine tumor, thyroid cancer, uterine cancer, liver cancer and the like (particularly, pancreatic cancer), and have a lower risk of prolonged side effects. The present invention provides a conjugate comprising a radioactive moiety comprising an aryl group substituted with a radionuclide selected from 211At, 210At, 131I, 125I, 124I, 123I, 77Br and 76Br, and a bioactive moiety having an affinity for fibroblast activation protein ? (FAP?).
Type:
Application
Filed:
February 21, 2023
Publication date:
July 16, 2026
Inventors:
Yoshifumi SHIRAKAMI, Yuichiro KADONAGA, Kazuko KANEDA, Tadashi WATABE, Koichi FUKASE, Atsushi SHIMOYAMA, Ayaka ASO, Taku Yoshiya